CMU’s New Research Findings against the Pandemic! President Mien-Chie Hung and Research Team Published Breakthrough Research in American Journal of Cancer Research
Date：August 31, 2020
A significant breakthrough in Taiwan’s anti-pandemic research! By applying the strategies and concepts of target therapy for cancer treatment and screening more than a thousand of small molecule compounds, China Medical University (CMU) President Mien-Chie Hung and the CMU anti-pandemic research team had found a core protease that can inhibit the replication of coronavirus. This major discovery “Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug” was published in the latest issue of American Journal of Cancer Research and was honorably selected as the cover story, which aroused great attention from international academic fields and medical institution.
Following the discovery of TFQ (an inhibitor that can effectively inhibit the activity of main protease of the coronavirus), the finding of the core protease that can inhibit the replication of coronavirus provides a strong evidence for further human clinical trials.
President Hung has been actively integrating the research team of CMU. From thousands of small molecular compounds, the research team initially screened out a broad-spectrum inhibitor GC376 that can effectively inhibit the activity of the main protease of the coronavirus. In addition, Professor Ye Chen in the team used cutting-edge equipment to analyze the complex 3D structure of the drug and the main protease of the virus. This is Taiwan’s first 3D structure of the protease for the drug treating coronavirus.
President Hung explained, “The replication and maturation of the coronavirus require the cleavage of the peptide pp1ab/pp1a through main protease, to produce the core protease required for virus replication. Therefore, the inhibitor GC376 can simulate the substrate of the main protease of the coronavirus and bind tightly to its active site, to inhibit virus replication.”
Taiwan has set an excellent example in the pandemic prevention of COVID-19. With the spirit of medical profession, CMU research team is dedicating to develop cutting-edge medical research, and invest into the development of target drugs for COVID-19.